Monte Rosa Therapeutics Inc — Cash Flow (NASDAQ:GLUE) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -59.36 M-92.47 M-43.8 M42 M-22.8 M -22.8 M Cash from investing activities -9.65 M-219.22 M88.8 M-44.45 M-101.83 M -101.83 M Cash from financing activities 377.56 M20.47 M27.49 M98.89 M30.35 M 30.35 M Free cash flow -69.09 M-105.38 M-62.84 M38.01 M-27.5 M -27.5 M

Haberler

Jefferies, Monte Rosa için hisse hedefini değerlemeye göre 30 dolara indirdi

Guggenheim, Monte Rosa hissesi için hedef fiyatı seyreltme nedeniyle 30 dolara düşürdü

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Monte Rosa Therapeutics gelir düşüşü ortasında rapor açıklayacak

Monte Rosa Therapeutics earnings on deck amid revenue decline

Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496

Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates

Monte Rosa hisseleri prostat kanseri deneme sonuçlarıyla yükseldi

Monte Rosa shares rise on prostate cancer trial results

Monte Rosa prostat kanseri ilacı için olumlu deneme verisi açıkladı